Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 24799285)

1.

Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.

Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D.

Mol Syst Biol. 2014 May 5;10:728. doi: 10.1002/msb.20134892.

2.

Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.

Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC.

Cytokine. 2012 Aug;59(2):228-36. doi: 10.1016/j.cyto.2012.04.020. Epub 2012 May 15.

PMID:
22595649
3.

Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells.

Caneba CA, Yang L, Baddour J, Curtis R, Win J, Hartig S, Marini J, Nagrath D.

Cell Death Dis. 2014 Jun 26;5:e1302. doi: 10.1038/cddis.2014.264.

PMID:
24967964
4.

Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion.

Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY.

Cytokine. 2012 Jul;59(1):145-55. doi: 10.1016/j.cyto.2012.04.013. Epub 2012 May 9.

PMID:
22579115
5.

Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.

Thériault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL.

Int J Cancer. 2012 Apr 15;130(8):1844-54. doi: 10.1002/ijc.26189. Epub 2011 Aug 5.

PMID:
21618518
6.

CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.

Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW Jr.

World J Surg Oncol. 2010 Jul 22;8:62. doi: 10.1186/1477-7819-8-62.

7.

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.

Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18782-7. doi: 10.1073/pnas.0810199105. Epub 2008 Nov 24.

8.

Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.

Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16. doi: 10.1016/j.ajog.2013.08.004. Epub 2013 Aug 9.

9.

Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.

Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, Chiaradonna F.

Mol Syst Biol. 2011 Aug 16;7:523. doi: 10.1038/msb.2011.56.

10.

An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids.

Pettee KM, Dvorak KM, Nestor-Kalinoski AL, Eisenmann KM.

PLoS One. 2014 Feb 28;9(2):e90371. doi: 10.1371/journal.pone.0090371. eCollection 2014.

11.

Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.

Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z.

Mol Cancer Res. 2008 Jun;6(6):917-28. doi: 10.1158/1541-7786.MCR-08-0093.

12.
13.

FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway.

Basu M, Mukhopadhyay S, Chatterjee U, Roy SS.

J Biol Chem. 2014 Jan 17;289(3):1415-28. doi: 10.1074/jbc.M113.535427. Epub 2013 Nov 19.

14.
15.

Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.

Ellerbroek SM, Hudson LG, Stack MS.

Int J Cancer. 1998 Oct 29;78(3):331-7.

PMID:
9766568
16.

Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.

Daye D, Wellen KE.

Semin Cell Dev Biol. 2012 Jun;23(4):362-9. doi: 10.1016/j.semcdb.2012.02.002. Epub 2012 Feb 11. Review.

PMID:
22349059
17.

Identification of LMX1B as a novel oncogene in human ovarian cancer.

He L, Guo L, Vathipadiekal V, Sergent PA, Growdon WB, Engler DA, Rueda BR, Birrer MJ, Orsulic S, Mohapatra G.

Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.

PMID:
24056967
18.

p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Strömblad S, Cheung AN.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18622-7. doi: 10.1073/pnas.0907481107. Epub 2010 Oct 6.

19.
20.

CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.

Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J.

Clin Cancer Res. 2010 Aug 1;16(15):3875-86. doi: 10.1158/1078-0432.CCR-10-0483. Epub 2010 May 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk